United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $470.43, for a total transaction of $10,584,675.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total transaction of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $429.25, for a total transaction of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.50, for a total transaction of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $427.41, for a total transaction of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $450.24, for a total value of $10,130,400.00.
• On Monday, September 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $421.80, for a total value of $9,490,500.00.
• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $416.35, for a total value of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The shares were sold at an average price of $392.21, for a total value of $1,961,050.00.

United Therapeutics Trading Up 1.0%

Shares of NASDAQ:UTHR opened at $476.59 on Wednesday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $485.32. The business has a 50 day moving average of $435.39 and a two-hundred day moving average of $352.54. The company has a market capitalization of $20.52 billion, a PE ratio of 18.06, a PEG ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter last year, the company earned $6.39 EPS. The business’s revenue was up 6.8% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. IFP Advisors Inc lifted its position in shares of United Therapeutics by 103.4% in the first quarter. IFP Advisors Inc now owns 1,739 shares of the biotechnology company’s stock valued at $536,000 after acquiring an additional 884 shares in the last quarter. Allianz Asset Management GmbH raised its stake in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after purchasing an additional 33,254 shares during the last quarter. KLP Kapitalforvaltning AS lifted its holdings in United Therapeutics by 37.6% in the 1st quarter. KLP Kapitalforvaltning AS now owns 59,600 shares of the biotechnology company’s stock valued at $18,373,000 after purchasing an additional 16,300 shares in the last quarter. Legato Capital Management LLC acquired a new stake in United Therapeutics during the 1st quarter worth $1,512,000. Finally, AE Wealth Management LLC acquired a new stake in United Therapeutics during the 1st quarter worth $248,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the subject of a number of recent analyst reports. Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Oppenheimer lifted their price target on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Wednesday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research report on Thursday, November 13th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $503.90.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.